TY - JOUR
T1 - Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort
AU - Orso, Beatrice
AU - Mattioli, Pietro
AU - Yoon, Eun-Jin
AU - Kim, Yu Kyeong
AU - Kim, Heejung
AU - Shin, Jung Hwan
AU - Kim, Ryul
AU - Liguori, Claudio
AU - Famà, Francesco
AU - Donniaquio, Andrea
AU - Massa, Federico
AU - García, David V. llez
AU - Meles, Sanne K.
AU - Leenders, Klaus L.
AU - Chiaravalloti, Agostino
AU - Pardini, Matteo
AU - Bauckneht, Matteo
AU - Morbelli, Silvia
AU - Nobili, Flavio
AU - Lee, Jee-Young
AU - Arnaldi, Dario
N1 - Funding Information: Open access funding provided by Università degli Studi di Genova within the CRUI-CARE Agreement. The study was partly supported by a grant from the Italian Ministry of Health to IRCCS Ospedale Policlinico San Martino (Fondi per la Ricerca Corrente 2019/2020, 5 × 1000 founding scheme, and Italian Neuroscience network (RIN)) and by a University of Genoa Curiosity Grant to M.P. The entire Korean cohort and PET data were supported by National Research Foundation (NRF) grant funded by the Ministry of Science and ICT(MSIT) in Korea (NRF-2022R1A2C4001834). Funding Information: This work was developed within the framework of the DINOGMI Department of Excellence of MIUR 2018-2022 (legge 232 del 2016). Publisher Copyright: © 2023, The Author(s).
PY - 2023/9
Y1 - 2023/9
N2 - Background: A brain glucose metabolism pattern related to phenoconversion in patients with idiopathic/isolated REM sleep behaviour disorder (iRBDconvRP) was recently identified. However, the validation of the iRBDconvRP in an external, independent group of iRBD patients is needed to verify the reproducibility of such pattern, so to increase its importance in clinical and research settings. The aim of this work was to validate the iRBDconvRP in an independent group of iRBD patients. Methods: Forty iRBD patients (70 ± 5.59 years, 19 females) underwent brain [18F]FDG-PET in Seoul National University. Thirteen patients phenoconverted at follow-up (7 Parkinson disease, 5 Dementia with Lewy bodies, 1 Multiple system atrophy; follow-up time 35 ± 20.56 months) and 27 patients were still free from parkinsonism/dementia after 62 ± 29.49 months from baseline. We applied the previously identified iRBDconvRP to validate its phenoconversion prediction power. Results: The iRBDconvRP significantly discriminated converters from non-converters iRBD patients (p = 0.016; Area under the Curve 0.74, Sensitivity 0.69, Specificity 0.78), and it significantly predicted phenoconversion (Hazard ratio 4.26, C.I.95%: 1.18–15.39). Conclusions: The iRBDconvRP confirmed its robustness in predicting phenoconversion in an independent group of iRBD patients, suggesting its potential role as a stratification biomarker for disease-modifying trials.
AB - Background: A brain glucose metabolism pattern related to phenoconversion in patients with idiopathic/isolated REM sleep behaviour disorder (iRBDconvRP) was recently identified. However, the validation of the iRBDconvRP in an external, independent group of iRBD patients is needed to verify the reproducibility of such pattern, so to increase its importance in clinical and research settings. The aim of this work was to validate the iRBDconvRP in an independent group of iRBD patients. Methods: Forty iRBD patients (70 ± 5.59 years, 19 females) underwent brain [18F]FDG-PET in Seoul National University. Thirteen patients phenoconverted at follow-up (7 Parkinson disease, 5 Dementia with Lewy bodies, 1 Multiple system atrophy; follow-up time 35 ± 20.56 months) and 27 patients were still free from parkinsonism/dementia after 62 ± 29.49 months from baseline. We applied the previously identified iRBDconvRP to validate its phenoconversion prediction power. Results: The iRBDconvRP significantly discriminated converters from non-converters iRBD patients (p = 0.016; Area under the Curve 0.74, Sensitivity 0.69, Specificity 0.78), and it significantly predicted phenoconversion (Hazard ratio 4.26, C.I.95%: 1.18–15.39). Conclusions: The iRBDconvRP confirmed its robustness in predicting phenoconversion in an independent group of iRBD patients, suggesting its potential role as a stratification biomarker for disease-modifying trials.
KW - Alpha-synucleinopathies
KW - Brain metabolic pattern
KW - Dementia with Lewy bodies
KW - Parkinson’s disease
KW - REM behaviour disorder
KW - [ F]FDG-PET
UR - http://www.scopus.com/inward/record.url?scp=85157991326&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s10072-023-06829-2
DO - https://doi.org/10.1007/s10072-023-06829-2
M3 - Article
C2 - 37140829
SN - 1590-1874
VL - 44
SP - 3161
EP - 3168
JO - Neurological sciences
JF - Neurological sciences
IS - 9
ER -